Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.
IPO Year: 1992
Exchange: NASDAQ
Website: orthofix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $24.00 | Buy | Canaccord Genuity |
| 11/8/2024 | $18.00 → $24.00 | Hold → Buy | Stifel |
| 5/8/2024 | $15.00 → $20.00 | Neutral → Buy | ROTH MKM |
| 10/20/2023 | $12.00 | Neutral | ROTH MKM |
| 9/12/2023 | Buy → Neutral | BTIG Research | |
| 9/12/2023 | Buy → Hold | Stifel | |
| 7/19/2023 | $27.00 | Buy | BTIG Research |
| 3/4/2022 | $41.00 → $45.00 | Hold → Buy | Stifel |
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa
Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port
Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319068728/en/TrueLok™ Elevate Transverse Bone Transport (TBT) System TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT procedure has previously been reported,1 TrueLok Elevat
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa
Monday, March 17, 2025 at 8:00 am Pacific Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th Annual Roth Conference in Dana Point, CA. Management is scheduled to present on Monday, March 17, 2025 at 8:00 am PT. Interested parties can access the live and archived webcast of the presentation in the "Events & Presentations" section of the Orthofix investor relations website at ir.orthofix.com. Internet Posting of Information Orthofix routinely posts information that may be important to investors in the "Investors" section of its website at www.orthofix.com. The Company encourages investors
Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account
Monday, March 10, 2025 at 9:00 am Pacific Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 9:00 am PT. Interested parties can access the live and archived webcast of the presentation in the "Events & Presentations" section of the Orthofix investor relations website at ir.orthofix.com. Internet Posting of Information Orthofix routinely posts information that may be important to investors in the "Investors" section of its website at www.orthofix.com. The Company enc
Company to Host Conference Call on Tuesday, February 25, 2025 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the event passcode 5184023. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Post
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Stifel 2024 Healthcare Conference in New York, NY, November 18, 2024, fireside chat at 8:35 AM Eastern Time Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach, CA, December 9, 2024, fireside chat at 8:00 AM Pacific Time Live webcasts and replays, when available, can be found under "Events & Presentations" in the Investors section of the Orthofix website at https://ir.orthofix.com/events-and-presentations/.
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
10-Q - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
DEFA14A - Orthofix Medical Inc. (0000884624) (Filer)
DEF 14A - Orthofix Medical Inc. (0000884624) (Filer)
SCHEDULE 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
S-3ASR - Orthofix Medical Inc. (0000884624) (Filer)
10-K - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa
Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O
Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account
Company to Host Conference Call on Tuesday, February 25, 2025 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the event passcode 5184023. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Post
Building on Positive Momentum from Compelling Combination of Profitable, Above-Market Growth with a Stronger Financial Profile Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third quarter 2024 net sales of $196.6 million, an increase of 7% on a reported and constant currency basis compared to third quarter 2023 U.S. Spine Fixation1 net sales growth of 18% compared to third quarter 2023, driven by distribution expansion and further penetration in existi
Company to Host Conference Call on Thursday, November 7, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2024 financial results on Thursday, November 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,
Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% compared to second quarter 2023, marking six consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 12% compared to second quarter 2023, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on
Company to Host Conference Call on Tuesday, August 6, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,
Recent Highlights Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year Bone Growth Therapies net sales growth of 10%, marking five consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 16%, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on a reported basis, primarily driven by U.S. Orthopedic net sales growth of 23% First quarter 2024 net loss of $36 million; Non-GAAP Adjusted EBITDA of $8 million, an increase of $4.5 million, a 220 basis point expansion over prior year Midpoint of full
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2024 financial results on Tuesday, May 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference call and
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00
Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously
ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously
ROTH MKM initiated coverage of Orthofix with a rating of Neutral and set a new price target of $12.00
BTIG Research downgraded Orthofix from Buy to Neutral
Stifel downgraded Orthofix from Buy to Hold
BTIG Research resumed coverage of Orthofix with a rating of Buy and set a new price target of $27.00
Stifel upgraded Orthofix Medical from Hold to Buy and set a new price target of $45.00 from $41.00 previously
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Michael Finegan as Chair of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624766470/en/Michael Finegan, Chair of the Orthofix Board of Directors. (Photo: Business Wire) Finegan was appointed to the Orthofix Board in December 2023. He is CEO at Acera Surgical, a bioscience company developing and commercializing a portfolio of fully engineered synthetic materials for soft tissue repair and regenerative medicine. Prior to joining Acera, Finegan spent 14 years at Orthofix where he served
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Aviva McPherron as President of Global Operations and Quality. As a member of the Executive Leadership Team, McPherron will oversee strategy for the company's operations, manufacturing, regulatory, clinical, and quality teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618902092/en/Aviva McPherron, President of Global Operations and Quality at Orthofix Medical Inc. (Photo: Business Wire) McPherron joins Orthofix from Globus Medical where she served as Senior Vice President, Clinical Services and Integrat
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Julie Dewey as Chief Investor Relations and Communications Officer. Additionally, as previously announced, Max Reinhardt begins as President of the company's global spine business. Dewey and Reinhardt will serve on Orthofix's Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611316728/en/Julie Dewey, Chief Investor Relations and Communications Officer, Orthofix Medical Inc. (Photo: Business Wire) A seasoned investor relations and communications executive, Dewey previously held roles a
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Max Reinhardt as President of the Global Spine business effective June 10, 2024. Reinhardt will serve on the Executive Leadership Team and be responsible for leading SeaSpine, the Company's global spine and biologics business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523192754/en/Max Reinhardt, incoming President of the Orthofix Global Spine business. (Photo: Business Wire) Reinhardt's experience spans more than 30 years in MedTech and pharmaceuticals, assuming positions of increasing responsibility at
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416821173/en/Andres Cedron, Chief Legal Officer for Orthofix (Photo: Business Wire) Cedron most recently served as Vice President and Corporate Secretary at Stryker Corporation, a $20B+ global medical device company. In his corporate officer position, Cedron oversaw Stryker's corporate governance, SEC compliance, mergers and acquisitions, and ESG matters. "With a broad breadth of experience in the medical device i
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Jason Shallenberger to President of the Bone Growth Therapies business, and the realignment of its Spine business unit, effective March 1. A seasoned sales leader, Shallenberger previously served as Vice President of U.S. Sales and Marketing for the Orthofix Bone Growth Therapies business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229167353/en/Orthofix names Jason Shallenberger as President, Bone Growth Therapies (Photo: Business Wire) Prior to this realignment, the Bone Growth Therapies business was ma
Massimo Calafiore begins as President and Chief Executive Officer, effective immediately Julie Andrews is appointed as Chief Financial Officer, assuming the role effective January 15, 2024 Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that effective immediately, Massimo Calafiore has assumed the role of President and Chief Executive Officer (CEO) and as a member of the Orthofix Board of Directors. In conjunction with Mr. Calafiore stepping into his role as CEO, the Company has announced the appointment of Julie Andrews as Chief Financial Officer. Ms. Andrews previously served as CFO for Smart Wires Technology, where she led all f